X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (975) 975
Publication (131) 131
Book Chapter (23) 23
Book Review (9) 9
Newsletter (8) 8
Magazine Article (6) 6
Conference Proceeding (4) 4
Newspaper Article (3) 3
Paper (1) 1
Trade Publication Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
boceprevir (992) 992
telaprevir (707) 707
index medicus (650) 650
humans (624) 624
hepatitis c (456) 456
hepatitis c virus (389) 389
hepatitis c, chronic - drug therapy (387) 387
antiviral agents - therapeutic use (385) 385
ribavirin (362) 362
gastroenterology & hepatology (309) 309
male (308) 308
female (288) 288
hepacivirus - genetics (276) 276
middle aged (265) 265
drug therapy, combination (260) 260
genotype (239) 239
protease inhibitors (229) 229
proline - analogs & derivatives (223) 223
treatment outcome (220) 220
ribavirin - therapeutic use (217) 217
genotype 1 infection (206) 206
interferon (206) 206
adult (201) 201
virus-infection (194) 194
hepacivirus - drug effects (192) 192
hepatitis (181) 181
interferon-alpha - therapeutic use (177) 177
pharmacology & pharmacy (173) 173
oligopeptides - therapeutic use (162) 162
sustained virological response (155) 155
antiviral agents - administration & dosage (152) 152
antiviral agents (151) 151
hepatitis c - drug therapy (149) 149
proline - therapeutic use (149) 149
drug therapy (147) 147
hepatitis c, chronic - virology (147) 147
infectious diseases (146) 146
polyethylene glycols - therapeutic use (145) 145
antiviral agents - adverse effects (144) 144
health aspects (144) 144
aged (141) 141
therapy (141) 141
hcv (135) 135
plus ribavirin (135) 135
proteases (131) 131
sofosbuvir (129) 129
peginterferon (127) 127
virology (124) 124
care and treatment (123) 123
gastroenterology and hepatology (122) 122
recombinant proteins - therapeutic use (121) 121
pegylated interferon (120) 120
biological response modifiers (108) 108
infection (106) 106
chronic hepatitis-c (105) 105
analysis (104) 104
virus diseases (102) 102
antiviral agents - pharmacology (97) 97
cirrhosis (96) 96
protease inhibitors - therapeutic use (96) 96
ribavirin - administration & dosage (96) 96
liver cirrhosis (95) 95
protease inhibitor (93) 93
triple therapy (89) 89
genetic aspects (88) 88
viral load (87) 87
liver (80) 80
hiv (79) 79
hepatology (77) 77
interferon-alpha - administration & dosage (77) 77
young adult (75) 75
antiviral therapy (73) 73
genotype & phenotype (72) 72
infections (72) 72
microbiology (72) 72
chronic hepatitis c (71) 71
medicine, general & internal (70) 70
proline - administration & dosage (70) 70
oligopeptides - adverse effects (69) 69
polyethylene glycols - administration & dosage (69) 69
rna, viral - blood (69) 69
simeprevir (69) 69
combination (68) 68
retrospective studies (67) 67
viral nonstructural proteins - antagonists & inhibitors (67) 67
genotype 1 (66) 66
proline - adverse effects (65) 65
drug interactions (63) 63
management (62) 62
abridged index medicus (61) 61
peginterferon alpha-2a (61) 61
recombinant proteins - administration & dosage (61) 61
fibrosis (60) 60
hepatitis c - virology (60) 60
hepatitis c, chronic - complications (60) 60
oligopeptides - administration & dosage (60) 60
treatment-naive patients (60) 60
liver diseases (59) 59
ribavirin - adverse effects (59) 59
hepacivirus - isolation & purification (58) 58
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (921) 921
Spanish (36) 36
Hungarian (19) 19
German (14) 14
French (13) 13
Czech (5) 5
Russian (4) 4
Croatian (1) 1
Italian (1) 1
Korean (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Microbiology and Infectious Diseases, ISSN 2146-3158, 03/2015, Volume 5, Issue 1, pp. 32 - 35
Boceprevir is a NS3/4A hepatitis C virus (HCV) protease inhibitor, used in combination with peginterferon and ribavirin to treat HCV. Boceprevir undergoes... 
boceprevir | Amlodipine
Journal Article
Hepatology, ISSN 0270-9139, 06/2013, Volume 57, Issue 6, pp. 2143 - 2154
Faldaprevir (BI 201335) is a potent, hepatitis C virus (HCV) NS3/4A protease inhibitor with pharmacokinetic properties supportive of once‐daily (QD) dosing.... 
NONRESPONSE | TELAPREVIR | THERAPY | HEPATITIS-C VIRUS | PEGINTERFERON ALPHA-2A | BI 201335 | PHARMACOKINETICS | PROTEASE INHIBITOR BI201335 | 1 INFECTION | BOCEPREVIR | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
LANCET INFECTIOUS DISEASES, ISSN 1473-3099, 07/2013, Volume 13, Issue 7, pp. 597 - 605
Background Rates of sustained virological response (SVR) to peginterferon-ribavirin are low in patients with hepatitis C virus (HCV) genotype land HIV. We... 
SUSTAINED VIROLOGICAL RESPONSE | MORTALITY | INFECTIOUS DISEASES | COINFECTED PATIENTS | MANAGEMENT | ALPHA-2A PLUS RIBAVIRIN | C VIRUS | INFECTED PATIENTS | HCV | HUMAN-IMMUNODEFICIENCY-VIRUS | PROTEASE INHIBITOR BOCEPREVIR
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2014, Volume 60, Issue 1, pp. 78 - 86
Background & Aims: Protease inhibitors (PI) with peginterferon/ ribavirin have significantly improved SVR rates in HCV G1 patients. Their use to treat HCV... 
Boceprevir | Protease inhibitors | Early virological response | HCV recurrence | Sustained virological response | Telaprevir | Drug-drug interaction | Liver transplantation
Journal Article
Annals of Pharmacotherapy, ISSN 1060-0280, 09/2011, Volume 45, Issue 9, pp. 1085 - 1093
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 20, pp. 1889 - 1898
Journal Article
Journal Article
Virus Research, ISSN 0168-1702, 12/2019, Volume 274, p. 197778
NS3 is an important therapeutic target for direct-acting antiviral (DAA) drugs. However, many patients treated with DAAs have unsustained virologic response... 
Treatment failure | Boceprevir | HCV | Resistance associated substitutions | Direct-acting antiviral
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9956, pp. 1756 - 1765
Journal Article
Hepatology, ISSN 0270-9139, 07/2015, Volume 62, Issue 1, pp. 79 - 86
Patients with hepatitis C virus (HCV) infection and cirrhosis are underrepresented in clinical trials of interferon‐free regimens of direct‐acting antiviral... 
INTERFERON |